tariquidar profile

ID Source	ID
PubMed CID	148201
CHEMBL ID	348475
CHEBI ID	177609
SCHEMBL ID	104163
SCHEMBL ID	21545178
MeSH ID	M0354765

Synonym
n-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1h)-yl)ethyl)phenyl)carbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide
1n-{4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolinyl)ethyl]phenyl}-4,5-dimethoxy-2-(3-quinolylcarboxamido)benzamide
bdbm50075373
HY-10550
n-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1h)-yl)ethyl)phenylcarbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide
xr9576
xr 9576
tariquidar (usan/inn)
206873-63-4
D06008
tariquidar ,
n-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide
CHEMBL348475 ,
xr-9576
unii-j58862dtvd
tariquidar [usan:inn:ban]
3-quinolinecarboxamide, n-(2-(((4-(2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl)phenyl)amino)carbonyl)-4,5-dimethoxyphenyl)-
j58862dtvd ,
3-quinolinecarboxamide,n-(2-(((4-(2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl)phenyl)amino)carbonyl)-4,5-dimethoxyphenyl)-
AKOS016008964
NCGC00346448-01
PB29709
CS-0722
tariquidar [mi]
tariquidar [who-dd]
n-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1h)-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide
tariquidar [usan]
tariquidar [inn]
S8028
MLS006011218
smr004702980
SCHEMBL104163
n-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxy-phenyl]quinoline-3-carboxamide
3-quinolinecarboxamide, n-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]-
c38h38n4o6
AC-31048
DTXSID10174746
mfcd09837824
EX-A231
HMS3653L21
CHEBI:177609
tariquidar, >=98% (hplc)
J-013523
NCGC00346448-06
tariquidar (xr9576)
SW219804-1
A857742
FT-0700261
BCP06102
AS-75190
n-[2-({4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl}carbamoyl)-4,5-dimethoxyphenyl]quinoline-3-carboxamide
DB06240
Q7686198
SCHEMBL21545178
CCG-270326
gtpl11787
compound 2 [pmid: 10098671]
r1h ,
NCGC00346448-08

Excerpt	Reference	Relevance
"Tariquidar is a novel inhibitor of P-gp that has been shown to reverse resistance to cytotoxic drugs in tumor cell lines and mouse xenografts."	( Ex vivo reversal of chemoresistance by tariquidar (XR9576). Charlton, PA; Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, SJ; Mills, L; Norris, D; Prin, A; Sharma, S; Whitehouse, PA, 2004)	1.31
"Tariquidar is a potent and selective third-generation P-gp inhibitor, and coadministration with ondansetron has shown improved ondansetron distribution to the CNS."	( Simultaneous quantification of ondansetron and tariquidar in rat and human plasma using a high performance liquid chromatography-ultraviolet method. Chiang, M; Chong, YE; Deshpande, K; Haroutounian, S; Kagan, L; Lee, JB, 2019)	1.49
"Tariquidar is a potent P-gp inhibitor but its mechanism is unknown."	( Tariquidar inhibits P-glycoprotein drug efflux but activates ATPase activity by blocking transition to an open conformation. Clarke, DM; Loo, TW, 2014)	2.57
"Tariquidar is a unique P-gp inhibitor because it locks the pump in a conformation that blocks drug efflux but activates ATPase activity."	( Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein. Clarke, DM; Loo, TW, 2015)	1.4
"Tariquidar is a potent Pgp antagonist, without significant side effects and much less pharmacokinetic interaction than previous Pgp antagonists. "	( A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Abraham, J; Bakke, S; Balis, F; Bates, SE; Chen, C; Dwyer, A; Edgerly, M; Fojo, T; Goldspiel, B; Robey, R; Rutt, A; Van Tellingen, O; Wilson, R, 2009)	2.05
"Tariquidar is a potent, specific, noncompetitive inhibitor of P-glycoprotein."	( Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Bates, SE; Fox, E, 2007)	2.5

Excerpt	Reference	Relevance
"Tariquidar derivatives have been described as potent and selective ABCG2 inhibitors. "	( Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP). Antoni, F; Bauer, S; Bause, M; Bernhardt, G; Buschauer, A; Jackson, SM; König, B; Locher, KP; Manolaridis, I; Scholler, M; Stark, SA, 2020)	3.44

Excerpt	Reference	Relevance
"Tariquidar pre-treatment resulted in significant increases of [(11)C]quinidine and [(11)C]laniquidar brain concentrations."	( [11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness. de Lange, EC; Eriksson, J; Koepp, M; Labots, M; Lammertsma, AA; Potschka, H; Rongen, M; Russmann, V; Schuit, R; Seeger, N; Syvänen, S; van Kooij, R; Verbeek, J; Voskuyl, RA; Windhorst, AD; Zellinger, C, 2013)	1.11
"Tariquidar pretreatment increased the magnitude of [(18) F]MPPF K(1) in hippocampus by a mean of 142% in the nonresponders, which significantly exceeded the 92% increase observed in the responder group."	( Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. Bartenstein, P; Bartmann, H; Böning, G; Cumming, P; Fuest, C; Just, T; la Fougere, C; Pekcec, A; Potschka, H; Schlichtiger, J; Soerensen, J; Wängler, B; Winter, P; Xiong, G, 2010)	1.08
"Tariquidar treatment also decreased flumazenil transport out of the brain by 73%, increased the volume of distribution in the brain by 24%, and did not influence B(max) or K(D), compared with baseline."	( Altered GABAA receptor density and unaltered blood-brain barrier transport in a kainate model of epilepsy: an in vivo study using 11C-flumazenil and PET. de Lange, EC; Eriksson, J; Labots, M; Lammertsma, AA; Syvänen, S; Tagawa, Y; Voskuyl, RA; Windhorst, AD, 2012)	1.1
"Pretreatment with tariquidar, a potent inhibitor of P-gp, increased brain uptake of [11C](R)-(-)-RWAY about 1.5-fold and the plasma free fraction about 1.8-fold."	( Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](R)-(-)-RWAY. Bacher, JD; Brown, AK; Gladding, RL; Hong, J; Ichise, M; Innis, RB; McCarron, JA; Pike, VW; Yasuno, F; Zoghbi, SS, 2006)	0.66

Excerpt	Reference	Relevance
" However, the causes of fentanyl-induced fatal adverse effects have not been thoroughly researched."	( P-Glycoprotein on Blood-Brain Barrier Plays a Vital Role in Fentanyl Brain Exposure and Respiratory Toxicity in Rats. Li, H; Yang, H; Yu, C; Yuan, M; Zhuang, X, 2018)	0.48

Excerpt	Reference	Relevance
"P-glycoprotein (Pgp) antagonists have been difficult to develop because of complex pharmacokinetic interactions and a failure to show meaningful results."	( A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Balis, FM; Bates, SE; Chen, CC; Chen, X; Draper, D; Figg, WD; Fojo, T; Gardner, ER; Kelly, RJ; Piekarz, RL; Robey, RW; Steinberg, SM; Venkatesan, AM, 2011)	0.59
"Tariquidar is well tolerated, with less observed systemic pharmacokinetic interaction than previous Pgp antagonists."	( A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Balis, FM; Bates, SE; Chen, CC; Chen, X; Draper, D; Figg, WD; Fojo, T; Gardner, ER; Kelly, RJ; Piekarz, RL; Robey, RW; Steinberg, SM; Venkatesan, AM, 2011)	2.03
" Besides, the simultaneous administration of elacridar and tariquidar did not significantly modify the pharmacokinetic parameters of loperamide."	( Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution. Beduneau, A; Gromand, J; Lamprecht, A; Montesinos, RN; Moulari, B; Pellequer, Y, 2014)	0.65
" This trial demonstrates that modulators of resistance can be evaluated in combination with chemotherapy, and pharmacokinetic and pharmacodynamic endpoints can be useful in determination of recommended dose in children and adolescents."	( Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX, 2015)	0.68

Excerpt	Reference	Relevance
" We report a phase I study using tariquidar (XR9576), a potent Pgp antagonist, in combination with vinorelbine."	( A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Abraham, J; Bakke, S; Balis, F; Bates, SE; Chen, C; Dwyer, A; Edgerly, M; Fojo, T; Goldspiel, B; Robey, R; Rutt, A; Van Tellingen, O; Wilson, R, 2009)	0.89
" In subsequent cycles, vinorelbine was administered with tariquidar."	( A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Abraham, J; Bakke, S; Balis, F; Bates, SE; Chen, C; Dwyer, A; Edgerly, M; Fojo, T; Goldspiel, B; Robey, R; Rutt, A; Van Tellingen, O; Wilson, R, 2009)	0.85
" Here we report the results of a pharmacokinetic and pharmacodynamic trial using a third-generation, potent, noncompetitive inhibitor of Pgp, tariquidar (XR9576), in combination with docetaxel."	( A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Balis, FM; Bates, SE; Chen, CC; Chen, X; Draper, D; Figg, WD; Fojo, T; Gardner, ER; Kelly, RJ; Piekarz, RL; Robey, RW; Steinberg, SM; Venkatesan, AM, 2011)	0.79
"In the first treatment cycle, the pharmacokinetics of docetaxel (40 mg/m(2)) were evaluated after day 1 and day 8 doses, which were administered with or without tariquidar (150 mg)."	( A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Balis, FM; Bates, SE; Chen, CC; Chen, X; Draper, D; Figg, WD; Fojo, T; Gardner, ER; Kelly, RJ; Piekarz, RL; Robey, RW; Steinberg, SM; Venkatesan, AM, 2011)	0.79
"To date, the in vitro-in vivo correlation (IVIVC) of P-glycoprotein (P-gp)-mediated drug-drug interaction (DDI) at the blood-brain barrier (BBB) in rats indicated that the cutoff value to significantly affect the brain penetration of digoxin was [I,unbound/Ki] of 1, where I,unbound is the unbound plasma concentration of P-gp inhibitors."	( Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans. Amano, N; Hirabayashi, H; Moriwaki, T; Sugimoto, H, 2013)	0.39
" To assess the toxicity, pharmacokinetics (PK), and pharmacodynamics of tariquidar, we conducted a phase I trial of tariquidar in combination with doxorubicin, docetaxel, or vinorelbine in children and adolescents with recurrent or refractory solid tumors."	( Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX, 2015)	0.91
"5, or 2 mg/kg) was administered alone and in combination with doxorubicin, docetaxel, or vinorelbine."	( Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX, 2015)	0.68
" When administered in combination with tariquidar, the clearance of docetaxel and vinorelbine was reduced compared to prior studies."	( Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX, 2015)	0.95
" This trial demonstrates that modulators of resistance can be evaluated in combination with chemotherapy, and pharmacokinetic and pharmacodynamic endpoints can be useful in determination of recommended dose in children and adolescents."	( Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX, 2015)	0.68

Excerpt	Reference	Relevance
" Very recently, an alternative use of ABCG2 inhibitors in enhancing the bioavailability of ABCG2 substrates has emerged."	( ABCG2: recent discovery of potent and highly selective inhibitors. Boumendjel, A; Di Pietro, A; Gauthier, C; Lecerf-Schmidt, F; Payen, L; Peres, B; Valdameri, G; Winter, E, 2013)	0.39
" Oral bioavailability of tariquidar was found to be low in humans requiring the compound to be administered intravenously, which hinders a broader clinical use."	( Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. Bauer, M; Eberl, S; Jäger, W; Kussmann, M; Langer, O; Maier-Salamon, A; Matzneller, P; Poeppl, W; Zeitlinger, M, 2018)	1.05
" Formulation A was a solution and formulation B was a microemulsion which was previously shown to improve the oral bioavailability of the structurally related P-gp inhibitor elacridar in mice."	( Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. Bauer, M; Eberl, S; Jäger, W; Kussmann, M; Langer, O; Maier-Salamon, A; Matzneller, P; Poeppl, W; Zeitlinger, M, 2018)	0.75
"In contrast to human data, the present study found a high bioavailability of tariquidar in rats after oral dosing."	( Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. Bauer, M; Eberl, S; Jäger, W; Kussmann, M; Langer, O; Maier-Salamon, A; Matzneller, P; Poeppl, W; Zeitlinger, M, 2018)	0.98
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Multiple-target inhibitors of efflux transporter can be overcome the resistance and improve the oral bioavailability of chemotherapy drugs."	( Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel. Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F, 2022)	0.72

Excerpt	Relevance	Reference
"This study suggests that intentional inhibition of ABCB1 and ABCG2 function at the blood-brain barrier is unlikely to significantly improve clinical outcome of imatinib with currently used dosing regimens."	( Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice. Figg, WD; Gardner, ER; Smith, NF; Sparreboom, A, 2009)	0.61
"We used microPET to map the dose-response to the novel P-glycoprotein (P-gp) inhibitor tariquidar (TQD) of the initial influx of the P-gp substrate [(18)F]-MPPF in rat brain, and to test for effects of P-gp inhibition on the subsequent binding of [(18)F]-MPPF to serotonin 5-HT(1A) receptors."	( Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. Bartenstein, P; Bartmann, H; Böning, G; Cumming, P; Förster, S; Gildehaus, FJ; Just, T; la Fougère, C; Minuzzi, L; Nowak, S; Potschka, H; Rominger, A; Rosa-Neto, P; Wagner, E; Wängler, B; Winter, P, 2010)	0.79
" The aim of this study was to evaluate the dose-response relationship of two potent P-gp inhibitors and to investigate if increased brain uptake of VPM mediated by P-gp inhibition can be used to assess regional differences in P-gp activity."	( Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Bankstahl, JP; Bankstahl, M; Brauner, R; Ding, X; Karch, R; Kuntner, C; Langer, O; Löscher, W; Meier, M; Müller, M; Stanek, J; Stundner, G; Wanek, T, 2010)	0.65
" We compared the dose-response relationship of tariquidar in humans with data obtained in rats using a similar methodology."	( Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Bankstahl, JP; Bauer, M; Böhmdorfer, M; Jäger, W; Karch, R; Koepp, M; Kuntner, C; Langer, O; Löscher, W; Matzneller, P; Mitterhauser, M; Müller, M; Stanek, J; Wadsak, W; Zeitlinger, M, 2012)	0.88
" The aim of this study was to determine the effect of dosing time on the pharmacokinetics and brain distribution of morphine."	( Diurnal variation in the pharmacokinetics and brain distribution of morphine and its major metabolite. de Lange, ECM; Hartman, R; Kervezee, L; Meijer, JH; van den Berg, DJ, 2017)	0.46
"Two different tariquidar formulations (A and B) were used, both at a dosage of 15 mg/kg, respectively."	( Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. Bauer, M; Eberl, S; Jäger, W; Kussmann, M; Langer, O; Maier-Salamon, A; Matzneller, P; Poeppl, W; Zeitlinger, M, 2018)	1.11
" After intraperitoneal dosing bioavailability was 91."	( Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. Bauer, M; Eberl, S; Jäger, W; Kussmann, M; Langer, O; Maier-Salamon, A; Matzneller, P; Poeppl, W; Zeitlinger, M, 2018)	0.75

Class	Description
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	11.5068	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
cytochrome P450 2D6	Homo sapiens (human)	Potency	10.6840	0.0010	8.3798	61.1304	AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 1A2	Homo sapiens (human)	IC50 (µMol)	27.2000	0.0001	1.7740	10.0000	AID295525
Cytochrome P450 2E1	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0140	1.6872	6.2000	AID295532
ATP-dependent translocase ABCB1	Mus musculus (house mouse)	IC50 (µMol)	0.0643	0.0640	4.0126	10.0000	AID326370
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	1.4278	0.0002	2.3185	10.0000	AID1277332; AID1328158; AID1328188; AID1328199; AID1328218; AID1328232; AID1328247; AID1328261; AID1486951; AID1486971; AID1486973; AID1486975; AID1486977; AID1486979; AID1530709; AID1530710; AID1668500; AID1690374; AID1690381; AID1750901; AID1761208; AID1761209; AID1761210; AID1761211; AID1761212; AID1761213; AID1761214; AID1761215; AID1766766; AID326367; AID326369; AID364884; AID370716; AID395103; AID578762; AID599027; AID672543; AID734840
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0001	1.7536	10.0000	AID295533; AID295534
Cytochrome P450 2C8	Homo sapiens (human)	IC50 (µMol)	45.3000	0.0008	1.8848	7.9000	AID295528
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0000	2.0151	10.0000	AID295531
Cytochrome P450 2A6	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0044	3.8895	10.0000	AID295526
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	7.1000	0.0000	2.8005	10.0000	AID295529
Cytochrome P450 2B6	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0011	3.4186	10.0000	AID295527
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0000	2.3983	10.0000	AID295530
Multidrug resistance-associated protein 1	Homo sapiens (human)	IC50 (µMol)	23.7800	0.0015	3.7110	9.6600	AID1766765
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	1.2363	0.0040	1.9666	10.0000	AID1277333; AID1385908; AID1690372; AID1766764; AID364887; AID370449; AID451987; AID451988; AID578759; AID578760; AID599026; AID734837
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-dependent translocase ABCB1	Homo sapiens (human)	EC50 (µMol)	0.0766	0.0160	0.6786	3.1000	AID1129602; AID1690379; AID1766774; AID295523; AID733672
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	EC50 (µMol)	0.0550	0.0054	0.4220	3.2000	AID1525951; AID733671
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2E1	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 2E1	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2E1	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2E1	Homo sapiens (human)
response to bacterium	Cytochrome P450 2E1	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2E1	Homo sapiens (human)
carbon tetrachloride metabolic process	Cytochrome P450 2E1	Homo sapiens (human)
benzene metabolic process	Cytochrome P450 2E1	Homo sapiens (human)
4-nitrophenol metabolic process	Cytochrome P450 2E1	Homo sapiens (human)
halogenated hydrocarbon metabolic process	Cytochrome P450 2E1	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2E1	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2E1	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 2C8	Homo sapiens (human)
organic acid metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C8	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C8	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C8	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C8	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C8	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C8	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2A6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2A6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2A6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2A6	Homo sapiens (human)
coumarin catabolic process	Cytochrome P450 2A6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2A6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2B6	Homo sapiens (human)
cellular ketone metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2B6	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
leukotriene metabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
response to xenobiotic stimulus	Multidrug resistance-associated protein 1	Homo sapiens (human)
cobalamin transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid biosynthetic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
cellular response to oxidative stress	Multidrug resistance-associated protein 1	Homo sapiens (human)
heme catabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
phospholipid translocation	Multidrug resistance-associated protein 1	Homo sapiens (human)
positive regulation of inflammatory response	Multidrug resistance-associated protein 1	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
cell chemotaxis	Multidrug resistance-associated protein 1	Homo sapiens (human)
transepithelial transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
cyclic nucleotide transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid translocation	Multidrug resistance-associated protein 1	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 1	Homo sapiens (human)
cellular response to amyloid-beta	Multidrug resistance-associated protein 1	Homo sapiens (human)
carboxylic acid transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Multidrug resistance-associated protein 1	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
lipid transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid biosynthetic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate metabolic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transmembrane transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transepithelial transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
renal urate salt excretion	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
export across plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
cellular detoxification	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2E1	Homo sapiens (human)
iron ion binding	Cytochrome P450 2E1	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2E1	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2E1	Homo sapiens (human)
4-nitrophenol 2-monooxygenase activity	Cytochrome P450 2E1	Homo sapiens (human)
oxygen binding	Cytochrome P450 2E1	Homo sapiens (human)
enzyme binding	Cytochrome P450 2E1	Homo sapiens (human)
heme binding	Cytochrome P450 2E1	Homo sapiens (human)
Hsp70 protein binding	Cytochrome P450 2E1	Homo sapiens (human)
Hsp90 protein binding	Cytochrome P450 2E1	Homo sapiens (human)
aromatase activity	Cytochrome P450 2E1	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2E1	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2E1	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2E1	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C8	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C8	Homo sapiens (human)
protein binding	Cytochrome P450 2C8	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C8	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 2C8	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C8	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C8	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 2C8	Homo sapiens (human)
heme binding	Cytochrome P450 2C8	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C8	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2A6	Homo sapiens (human)
coumarin 7-hydroxylase activity	Cytochrome P450 2A6	Homo sapiens (human)
enzyme binding	Cytochrome P450 2A6	Homo sapiens (human)
heme binding	Cytochrome P450 2A6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2A6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2A6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-alpha-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
heme binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-beta-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2B6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type vitamin B12 transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
mitochondrial inner membrane	Cytochrome P450 2E1	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2E1	Homo sapiens (human)
cytoplasm	Cytochrome P450 2E1	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2E1	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C8	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C8	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C8	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C8	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C8	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2A6	Homo sapiens (human)
cytoplasmic microtubule	Cytochrome P450 2A6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2A6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2A6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2B6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2B6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2B6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basal plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
lateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
extracellular exosome	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (326)

Assay ID	Title	Year	Journal	Article
AID733668	Activity at MDR1 (unknown origin) expressed in MDCK cells assessed as ATPase activity at 50 uM after 2 hrs by ATPlite assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp.
AID1766778	Apparent permeability from apical to basolateral side in MDCK-II cells after 120 mins by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
AID1832628	Chemo-sensitizing activity against human HEK293 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID67781	Reversal effect on the accumulation of [3H]- daunorubicin in mouse mammary carcinoma cell line EMT6/AR 1.0	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives.
AID1486978	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured after 12 hrs by MTT assay relative to ADR alone	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1673430	Reversal of P-gp mediated multidrug resistance in human K562/A02 cells overexpressing P-gp assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 5 uM preincubated for 24 hrs followed by compound washout and later in	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID1904129	Cytotoxicity against dog MDCK-II-BCRP cells after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1631741	Cytotoxicity against HLF cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1673423	Reversal of P-gp mediated multidrug resistance in human K562/A02 cells overexpressing P-gp assessed as fold reduction in doxorubicin IC50 at 5 uM preincubated for 24 hrs followed by compound washout and 24 hrs later incubated with doxorubicin and measured	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID1244200	Cytotoxicity against human SW620/AD300 cells assessed as cell viability after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1832572	Chemo-sensitizing activity against ABCB1-overexpressing human NCI/ADR-RES cells assessed as paclitaxel IC50 at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay (Rvb = 7.09 +/-0.89 microM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1832598	Chemo-sensitizing activity against human KB 3-1 cells assessed as paclitaxel IC50 at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay (Rvb = 2.29 +/-0.75 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1328269	Induction of apoptosis in human KB-3-1 cells assessed as viable cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 88.4%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID733672	Activity at MDR1 (unknown origin) expressed in MDCK cells using calcein AM as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by fluorometric analysis	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp.
AID1750946	Potentiation of adriamycin-induced apoptosis in human K562 cells assessed as necrotic cells at 5 uM incubated for 48 hrs in presence of 10 uM adriamycin by Annexin-V/FITC-based flow cytometry (Rvb = 7%)
AID680895	TP_TRANSPORTER: drug resistance (vinblastine) in NCI/ADRRes cells	2004	European journal of cancer (Oxford, England : 1990), Mar, Volume: 40, Issue:4	Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
AID578760	Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID1486975	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured after 6 hrs by MTT assay (Rvb = 51.34 +/- 5.1 uM)	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1815939	Stimulation of P-gp in human multidrug resistant NCI-H460/R cells assessed as fluorescence activity ratio at 50 uM for 30 mins by Rho123 accumulation assay relative to control
AID1832590	Chemo-sensitizing activity against ABCB1-overexpressing human KB-V1 cells assessed as vincristine IC50 at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay (Rvb = 1745 +/-293.01 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1328276	Induction of apoptosis in human KBV1 cells assessed as necrotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 1%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1832492	Chemo-sensitizing activity against ABCB1-overexpressing human NCI/ADR-RES cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1328288	Inhibition of ABCB1 in human NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine resistance ratio at 1000 nM after 72 hrs by MTT assay relative to parental OVCAR8 cells (Rvb = 59 No_unit)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID326369	Inhibition of Pgp by daunorubicin accumulation assay	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors.
AID733669	Efflux ratio of apparent permeability from basolateral to apical to apical to basolateral side of human Caco2 cells after 120 mins	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp.
AID1631731	Inhibition of P-gp mediated efflux in adriamycin-resistant human HepG2 cells assessed as intracellular rhodamine-123 accumulation at 1 uM incubated in dark condition for 90 mins by flow cytometry	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID370720	Inhibition of ABCC2 overexpressed in MDCK cells at 100 uM up to 50 uM by flow cytometric-based chloromethylfluorescein-diacetate accumulation assay	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
AID1832607	Chemo-sensitizing activity against ABCB1-overexpressing human KB-V1 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1815942	Stimulation of P-gp in human multidrug resistant NCI-H460/R cells assessed as fluorescence activity ratio at 0.05 uM for 72 mins by Rho123 accumulation assay relative to control
AID1750899	Cytotoxicity against MDCK-II cells incubated for 48 hrs by MTT assay
AID1244224	Cytotoxicity against human LCC6 cells at 200 nM after 72 hrs by SRB assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1832581	Chemo-sensitizing activity against human OVCAR-8 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1391812	Inhibition of P-gp in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring fold reduction in adriamycin IC50 at 5 uM preincubated for 24 hrs followed by compound wash out and subsequent addition of adriamycin after	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors.
AID1328232	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID497580	Biodistribution in mouse brain	2010	Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15	Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
AID1690377	Inhibition of human ABCC1 transfected in MDCK2-MRP1 cells up to 100 uM using calcein-AM as substrate measured after 1 hr by fluorescence assay relative to control	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1750929	Inhibition of BCRP-mediated multidrug resistance in MDCK-II cells assessed as mitoxantrone accumulation at 0.1 to 5 uM pretreated 1 hr followed by treated with mitoxantrone measured after 180 mins by flow cytometry
AID1486973	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured immediately by MTT assay (Rvb = 51.34 +/- 5.1 uM)	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1750926	Inhibition of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as Adriamycin accumulation at 1 to 10 uM pretreated 1 hr followed by treated with adriamycin measured after 180 mins by fluorescence microscopy
AID1328270	Induction of apoptosis in human KB-3-1 cells assessed as early apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 5.1%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1244213	Inhibition of BCRP in human MCF-7 FLV1000 cells assessed as increase of mitoxantrone-induced cytotoxicity at 200 nM after 72 hrs by SRB assay relative to control	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1244215	Inhibition of p-glycoprotein in human HepG2 cells assessed as increase of doxorubicin-induced cytotoxicity at 200 nM after 72 hrs by SRB assay relative to control	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1673435	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID734834	Ratio of compound IC50 to elacridar IC50 for ABCG2 in human MCF7/Topo cells after 2 hrs by Hoechst 33342 microplate assay	2013	ACS medicinal chemistry letters, Apr-11, Volume: 4, Issue:4	Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.
AID295530	Inhibition of human CYP2C19 expressed in insect microsome after 30 mins	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID1832634	Chemo-sensitizing activity against human HEK293 cells assessed as paclitaxel IC50 at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay (Rvb = 2.67 +/-0.39 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1244216	Potentiation of doxorubicin-induced cytotoxicity against human SW620 cells at 200 nM after 72 hrs by SRB assay relative to control	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID295532	Inhibition of human CYP2E1 expressed in insect microsome after 45 mins	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID295534	Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID1277336	Inhibition of ABCG2 in human MCF7/Topo cells at 10 uM by Hoechst 33342 assay relative to fumitremorgin C	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization.
AID1631730	Inhibition of P-gp mediated efflux in adriamycin-resistant human HepG2 cells assessed as intracellular rhodamine-123 accumulation at 0.125 uM incubated in dark condition for 90 mins by flow cytometry relative to control	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1673425	Reversal of P-gp mediated multidrug resistance in human K562/A02 cells overexpressing P-gp assessed as fold reduction in doxorubicin IC50 at 5 uM preincubated for 24 hrs followed by compound washout and 12 hrs later incubated with doxorubicin and measured	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID1244201	Cytotoxicity against human CCD-18Co cells assessed as cell viability after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1690382	Inhibition of sulfasalazine-stimulated ABCB1 ATPase activity (unknown origin) expressed in baculovirus infected Sf9 insect cells using ATP as substrate measured after 1 hr by colorimetric assay relative to FTC	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1244212	Potentiation of mitoxantrone-induced cytotoxicity against human MCF7 cells at 200 nM after 72 hrs by SRB assay relative to control	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1328281	Inhibition of ABCB1 in human KBV1 cells assessed as potentiation of colchicine-induced apoptosis by measuring viable cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 79.3%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1673433	Reversal of P-gp mediated multidrug resistance in human K562/A02 cells overexpressing P-gp assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 5 uM after 48 hrs by MTT assay (Rvb = 55.47 +/- 1.67 uM)	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID106130	Potency tested against multidrug resistance (MDR) cell lines expressing P-gp (P-glycoprotein)	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives.
AID1328283	Inhibition of ABCB1 in human KBV1 cells assessed as potentiation of colchicine-induced apoptosis by measuring late apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 9%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1738699	Inhibition of P-gp-mediated doxorubicin efflux in human K562/4 cells assessed as minimal concentration required for the effect by flow cytometric analysis	2020	European journal of medicinal chemistry, Jul-15, Volume: 198	Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin.
AID1382325	Substrate activity at P-gp in human K562/4 cells assessed as test compound accumulation at 1 uM after 1 to 24 hrs by flow cytometry	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	New antitumor anthra[2,3-b]furan-3-carboxamides: Synthesis and structure-activity relationship.
AID1832601	Chemo-sensitizing activity against ABCB1-expressing human KB-V1 cells assessed as paclitaxel IC50 at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay (Rvb = 2.73 +/-0.42 microM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1832640	Chemo-sensitizing activity against human HEK293 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1631739	Intrinsic cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1674910	Growth inhibition of human MCF7 upto 10 uM incubated for 48 hrs	2020	Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18	Mdm2 inhibitors as a platform for the design of P-glycoprotein inhibitors.
AID1631735	Reversal of P-gp-mediated resistance in adriamycin-resistant human HepG2 cells assessed as reduction in ADR IC50 at 100 nM after 48 hrs by MTT assay relative to control	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1244214	Potentiation of doxorubicin-induced cytotoxicity against human HepG2 cells at 200 nM after 72 hrs by SRB assay relative to control	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1328275	Induction of apoptosis in human KBV1 cells assessed as late apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 7.6%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID734840	Inhibition of ABCB1 in human KBV1 cells after 10 mins by Calcein-AM microplate assay	2013	ACS medicinal chemistry letters, Apr-11, Volume: 4, Issue:4	Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.
AID1388649	Binding affinity to P-gp (unknown origin)	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
AID1631733	Reversal of P-gp-mediated resistance in adriamycin-resistant human HepG2 cells assessed as reduction in ADR IC50 at 200 nM after 48 hrs by MTT assay relative to control	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1690373	Inhibition of ABCG2 in topotecan-cultured human MCF7 cells using Hoechst 33342 as substrate measured after 2 hrs by fluorescence assay relative to FTC	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1750944	Potentiation of adriamycin-induced apoptosis in human K562 cells assessed as early apoptotic cells at 5 uM incubated for 48 hrs in presence of 10 uM adriamycin by Annexin-V/FITC-based flow cytometry (Rvb = 22.3%)
AID1761212	Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 5 uM measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
AID1328278	Potentiation of colchicine-induced apoptosis in human KB-3-1 cells assessed as early apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 30.5%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1832646	Chemo-sensitizing activity against human HEK293 cells assessed as colchicine IC50 at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay (Rvb = 15.36 +/-6.18 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID326367	Inhibition of human Pgp in A2780 cells after 30 mins by Hoechst 33342 assay	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors.
AID1832631	Chemo-sensitizing activity against ABCB1-overexpressing human HEK293/MDR19 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1530710	Reversal of P-gp-mediated drug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 5 uM after 72 hrs by MTT assay (Rvb = 398.34 +/- 0.58 uM)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents.
AID1353439	Inhibition of P-gp in human K562/Dox cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring ratio of doxorubicin IC50 to doxorubicin IC50 in presence of test compound at 1 uM after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Mar-10, Volume: 147	Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
AID1690374	Inhibition of ABCB1 in human KB-V1 cells using calcein-AM as substrate measured after 10 mins by fluorescence assay	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID295528	Inhibition of human CYP2C8 expressed in insect microsome after 30 mins	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID1750900	Cytotoxicity against BCRP-overexpressing MDCK-II cells incubated for 48 hrs by MTT assay
AID1904131	Reversal of BCRP-mediated multidrug resistance in dog MDCK-II-BCRP cells assessed as potentiation of mitoxantrone-induced cytotoxicity at 5 uM by measuring mitoxantrone IC50 after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1244199	Cytotoxicity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1903297	Potentiation of mitoxantrone-induced cytotoxicity against human KBV cells assessed as mitoxantrone IC50 by measuring ratio IC50 as reversal fold at 5 uM for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles.
AID1832595	Chemo-sensitizing activity against ABCB1-overexpressing human KB-V1 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1832604	Chemo-sensitizing activity against human KB 3-1 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID578762	Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID1903295	Potentiation of paclitaxel-induced cytotoxicity against human KBV cells assessed as paclitaxel IC50 by measuring ratio IC50 as reversal fold at 5 uM for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles.
AID1328279	Potentiation of colchicine-induced apoptosis in human KB-3-1 cells assessed as late apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 25.7%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1750898	Cytotoxicity against P-gp overexpressing human K562/A02 cells incubated for 48 hrs by MTT assay
AID1328256	Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1328261	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1244221	Cytotoxicity against human HepG2 cells expressing p-glycoprotein at 200 nM after 72 hrs by SRB assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID364887	Inhibition of ABCG2 in human mitoxantrone-resistant MCF7 cells by Hoechst 33342 assay	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
AID1761210	Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 5 uM measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
AID1244210	Potentiation of paclitaxel-induced cytotoxicity against human LCC6 cells at 200 nM after 72 hrs by SRB assay relative to control	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1244217	Inhibition of p-glycoprotein in human SW620/AD300 cells assessed as increase of doxorubicin-induced cytotoxicity at 200 nM after 72 hrs by SRB assay relative to control	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1673434	Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as cell growth inhibition after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID295525	Inhibition of human CYP1A2 expressed in insect microsome after 15 mins	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID1328247	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID370450	Inhibition of ABCG2 over-expressed in human MCF7/Topo cells at 7 to 10 uM by flow cytometric-based mitoxantrone efflux assay relative to fumitremorgin C	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
AID1129602	Inhibition of P-glycoprotein (unknown origin) expressed in MDCK cells assessed as reduction of calcein-AM transport after 30 mins by fluorescence assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	SAR study on arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity.
AID1328272	Induction of apoptosis in human KB-3-1 cells assessed as necrotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 0.7%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1244218	Cytotoxicity against human SW620 cells at 200 nM after 72 hrs by SRB assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID497579	inhibition of P-glycoprotein in mdr1 deficient mouse lymphocyte	2010	Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15	Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
AID1673432	Reversal of P-gp mediated multidrug resistance in human K562/A02 cells overexpressing P-gp assessed as fold reduction in doxorubicin IC50 at 5 uM after 48 hrs by MTT assay relative to control	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID1525951	Inhibition of BCRP (unknown origin)	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID395103	Inhibition of P-glycoprotein-mediated multidrug resistance in adriamycin-resistant human A2780/ADR cells by calcein AM assay	2009	Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6	Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators.
AID1486981	Cytotoxicity against human K562 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1750901	Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM by measuring adriamycin IC50 after 48 hrs by MTT assay
AID1486972	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring reduction in ADR IC50 measured after 48 hrs by MTT assay relative to ADR alone	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1328242	Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID734837	Inhibition of ABCG2 in human MCF7/Topo cells after 2 hrs by Hoechst 33342 microplate assay	2013	ACS medicinal chemistry letters, Apr-11, Volume: 4, Issue:4	Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.
AID1815941	Stimulation of P-gp in human multidrug resistant NCI-H460/R cells assessed as decrease in Rho123 accumulation by measuring mean fluorescence intensity at 0.05 uM incubated for 72 hour followed by rhodamine 123 measured after 30 mins by flow cytometry
AID497578	Inhibition of MRP	2010	Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15	Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
AID1328184	Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1668500	Reversal of human ABCB1-mediated multidrug resistance in HEK293/MDR19 cells assessed as effect on colchicine-induced cytotoxicity at 1 uM by measuring colchine IC50 after 72 hrs by CCK8 assay (Rvb = 97.58 +/- 17.62 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1673428	Reversal of P-gp mediated multidrug resistance in human K562/A02 cells overexpressing P-gp assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 5 uM preincubated for 24 hrs followed by compound washout and 6 hrs la	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID1385908	Inhibition of ABCG2 in human MCF7/Topo cells after 2 hrs by Hoechst 33342 staining based fluorescence assay	2018	ACS medicinal chemistry letters, Aug-09, Volume: 9, Issue:8	Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators.
AID1903287	Potentiation of paclitaxel-induced cytotoxicity against human KBV cells assessed as paclitaxel IC50 at 5 uM for 72 hrs by MTT assay (Rvb = 1199.11 +/- 51.46 nM )	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles.
AID1766764	Inhibition of sulfasalazine-stimulated BCRP ATP ase activity (unknown origin)	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
AID1391811	Inhibition of P-gp in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring fold reduction in adriamycin IC50 at 5 uM preincubated for 24 hrs followed by compound wash out and subsequent addition of adriamycin after	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors.
AID1690380	Activation of ABCB1 ATPase activity (unknown origin) expressed in baculovirus infected Sf9 insect cells using ATP as substrate measured after 1 hr by colorimetric assay relative to sulfasalazine	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID497577	Inhibition of BCRP	2010	Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15	Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
AID1631738	Reversal of P-gp-mediated resistance in human MCF7/ADR cells assessed as reduction in ADR IC50 at 200 nM after 48 hrs by MTT assay relative to control	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1750903	Reversal of BCRP-mediated multidrug resistance in MDCK-II cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM by measuring adriamycin IC50 after 48 hrs by MTT assay
AID733670	Activity at MRP1 (unknown origin) expressed in MDCK cells using calcein AM as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by fluorometric analysis	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp.
AID295526	Inhibition of human CYP2A6 expressed in insect microsome after 15 mins	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID1903291	Potentiation of vincristine-induced cytotoxicity against human KBV cells assessed as vincristine IC50 at 5 uM for 72 hrs by MTT assay (Rvb = 1542.76 +/- 827.23 nM )	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles.
AID1391809	Inhibition of P-gp in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring fold reduction in adriamycin IC50 at 5 uM preincubated for 24 hrs followed by compound wash out and subsequent addition of adriamycin measu	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors.
AID1486952	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring reduction in ADR IC50 at 5 uM measured after 48 hrs by MTT assay relative to ADR alone	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1761213	Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
AID1486974	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured immediately by MTT assay relative to ADR alone	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1673429	Reversal of P-gp mediated multidrug resistance in human K562/A02 cells overexpressing P-gp assessed as fold reduction in doxorubicin IC50 at 5 uM preincubated for 24 hrs followed by compound washout and later incubated with doxorubicin and measured after	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID1866818	Inhibition of P-gp-mediated rhodamine-123 efflux in human COLO 320 cells assessed as fluorescence activity ratio at 0.2 uM preincubated for 10 mins followed by rhodamine-123 addition and measured after 20 mins by flow cytometry (Rvb = 0.828 No_unit)	2022	Journal of natural products, 04-22, Volume: 85, Issue:4	Triterpenes from
AID1391813	Inhibition of P-gp in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring fold reduction in adriamycin IC50 at 5 uM preincubated for 24 hrs followed by adriamycin addition measured after 48 hrs by MTT assay relati	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors.
AID1738698	Inhibition of P-gp-mediated doxorubicin efflux in human K562/4 cells assessed as increase in doxorubicin accumulation by flow cytometric analysis	2020	European journal of medicinal chemistry, Jul-15, Volume: 198	Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin.
AID1673441	Effect on P-gp expression in human K562/A02 cells overexpressing P-gp at 5 uM after 72 hrs by Western blot analysis	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID1673437	Inhibition of P-gp overexpressed in human K562/A02 cells assessed as increase in doxorubicin accumulation preincubated for 60 mins followed by doxorubicin addition and measured after 90 mins by fluorescence spectrophotometry analysis	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID1244198	Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1055011	Inhibition of human MDR1 expressed in MDCK2 cells assessed as increase of rhodamine 123 uptake at 5 uM up to 240 mins relative to control	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication.
AID1328271	Induction of apoptosis in human KB-3-1 cells assessed as late apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 5.8%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1673426	Reversal of P-gp mediated multidrug resistance in human K562/A02 cells overexpressing P-gp assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 5 uM preincubated for 24 hrs followed by compound washout and 12 hrs l	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID1328204	Inhibition of ABCB1 in human KBV1 cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine resistance ratio at 1000 nM after 72 hrs by MTT assay relative to parental KB-3-1 cells (Rvb = 55 No_unit)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1853004	Cytotoxicity against human HCT-116 cells assessed as reduction on cell viability at 1 uM incubated for 48 hrs by MTT assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1328194	Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 1000 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1750928	Inhibition of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as Adriamycin accumulation pretreated 1 hr followed by treated with adriamycin measured after 180 mins by flow cytometry
AID1904132	Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as fold reduction in adriamycin IC50 at 5 uM measured after 48 hrs by MTT assay relative to adriamycin IC50 alone	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1690379	Activation of ABCB1 ATPase activity (unknown origin) expressed in baculovirus infected Sf9 insect cells using ATP as substrate measured after 1 hr by colorimetric assay	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1903293	Potentiation of cisplatin-induced cytotoxicity against human KBV cells assessed as cisplatin IC50 at 5 uM for 72 hrs by MTT assay (Rvb = 6.28 +/- 1.23 nM )	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles.
AID1391801	Inhibition of P-gp in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring fold reduction in adriamycin IC50 at 5 uM after 48 hrs by MTT assay relative to adriamycin alone	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors.
AID1328280	Potentiation of colchicine-induced apoptosis in human KB-3-1 cells assessed as necrotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 4.9%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID370449	Inhibition of ABCG2 overexpressed in human MCF7/Topo cells by flow cytometric-based mitoxantrone efflux assay	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
AID1761211	Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 10 uM measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
AID1244202	Cytotoxicity against human HFE cells assessed as cell viability after 72 hrs by MTT assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1815940	Selectivity index, ratio of mean fluorescence intensity for stimulation of P-gp in human multidrug resistant NCI-H460/R cells to mean fluorescence intensity for stimulation of P-gp in human NCI-H460 cells assessed as decrease in Rho123 accumulation at 50
AID1486971	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 measured after 48 hrs by MTT assay (Rvb = 51.34 +/- 5.1 uM)	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1328158	Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 1000 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1328213	Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1244211	Inhibition of p-glycoprotein in human LCC6/MDR cells assessed as increase of paclitaxel-induced cytotoxicity at 200 nM after 72 hrs by SRB assay relative to control	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1904133	Reversal of BCRP-mediated multidrug resistance in dog MDCK-II-BCRP cells assessed as fold reduction in mitoxantrone IC50 at 5 uM measured after 48 hrs by MTT assay relative to mitoxantrone IC50 alone	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1328277	Potentiation of colchicine-induced apoptosis in human KB-3-1 cells assessed as viable cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 38.9%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID295533	Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID1328287	Inhibition of ABCB1 in human KBV1 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine resistance ratio at 1000 nM after 72 hrs by MTT assay relative to parental KB-3-1 cells (Rvb = 356 No_unit)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1815943	Selectivity index, ratio of mean fluorescence intensity for stimulation of P-gp in human multidrug resistant NCI-H460/R cells to mean fluorescence intensity for stimulation of P-gp in human NCI-H460 cells assessed as decrease in Rho123 accumulation at 0.0
AID1690243	Inhibition of P-gp in human U87-TxR cells assessed as increase in Rho123 accumulation at 50 nM measured after 30 mins by flow cytometry	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Further exploration of DVD-445 as a lead thioredoxin reductase (TrxR) inhibitor for cancer therapy: Optimization of potency and evaluation of anticancer potential.
AID1766774	Inhibition of P-gp (unknown origin) expressed in MES-SA/DX5 cells assessed as cell growth inhibition after 3 days in presence of 200 nM paclitaxel by MTT assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
AID733671	Activity at BCRP (unknown origin) expressed in MDCK cells using rhodamine 123 as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by fluorometric analysis	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp.
AID1761214	Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 5 uM measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
AID1832566	Chemo-sensitizing activity against ABCB1-overexpressing human NCI/ADR-RES cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID295523	Reversal of P-gp-mediated multidrug resistance to vinblastine in human CEM/VLB500 cells after 3 days by resazurin assay	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID1750902	Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM by after 48 hrs by MTT assay relative to control
AID1486977	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured after 12 hrs by MTT assay (Rvb = 51.34 +/- 5.1 uM)	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1631737	Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1832649	Chemo-sensitizing activity against ABCB1-overexpressing human HEK293/MDR19 cells assessed as colchicine IC50 at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay (Rvb = 260 +/-74.23 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1419462	Inhibition of P-gp in human K562/DOX cells assessed as increase in rhodamine-123 efflux in human K562 cells at 1 uM incubated for 10 mins hrs by flow cytometry relative to untreated control	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	N-alkanol-N-cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy.
AID451988	Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay	2010	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1	Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
AID295527	Inhibition of human CYP2B6 expressed in insect microsome after 30 mins	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID672543	Inhibition of P-glycoprotein-mediated daunorubicin efflux from human CCRF-CEM/VCR1000 cells after 240 secs by FACS flow cytometric analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.
AID1486980	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured after 24 hrs by MTT assay relative to ADR alone	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1832578	Chemo-sensitizing activity against ABCB1-overexpressing human NCI/ADR-RES cells assessed as colchicine IC50 at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay (Rvb = 2.63 +/-0.62 microM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1328274	Induction of apoptosis in human KBV1 cells assessed as early apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 5.3%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1750945	Potentiation of adriamycin-induced apoptosis in human K562 cells assessed as late apoptotic cells at 5 uM incubated for 48 hrs in presence of 10 uM adriamycin by Annexin-V/FITC-based flow cytometry (Rvb = 17.9%)
AID1328199	Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 487.57 +/- 30.54 nM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1244203	Cytotoxicity against rat hepatocytes assessed as cell viability after 72 hrs by MTT assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID370716	Inhibition of ABCB1 overexpressed in human KBv1 cells by flow cytometric-based calcein-AM efflux assay	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
AID1761208	Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 5 uM measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
AID1832610	Chemo-sensitizing activity against human KB 3-1 cells assessed as colchicine IC50 at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay (Rvb = 13.78 +/-7.63 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1328188	Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 5.07 +/- 0.19 uM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1832438	Chemo-sensitizing activity against human OVCAR-8 cells assessed as vincristine IC50 at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay (Rvb = 6.01 +/-0.77 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1277332	Inhibition of ABCB1 in human KBV1 cells assessed as inhibition of calcein-AM efflux	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization.
AID1904130	Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM by measuring adriamycin IC50 after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1631732	Inhibition of P-gp mediated efflux in adriamycin-resistant human HepG2 cells assessed as intracellular rhodamine-123 accumulation at 10 uM incubated in dark condition for 90 mins by flow cytometry relative to control	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1832435	Chemo-sensitizing activity against ABCB1-overexpressing human NCI/ADR-RES cells assessed as vincristine IC50 at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay (Rvb = 5.57 +/-0.96 microM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1766765	Inhibition of NEM-GS-stimulated MRP1 ATPase activity (unknown origin) in presence of GSH	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
AID1328153	Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 1000 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1832622	Chemo-sensitizing activity against human HEK293 cells assessed as vincristine IC50 at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay (Rvb = 2.29 +/-0.35 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1766767	Aqueous solubility of compound at pH 5.5	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
AID442337	Increase in P-gp-substrate 99mTc]sestaMIBI accumulation in liver of human with metastatic cancer at 150 mg, iv by imaging analysis	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials.
AID734836	Inhibition of ABCG2 in human MCF7/Topo cells at 70 to 100 uM after 2 hrs by Hoechst 33342 microplate assay relative to 10 uM fumitremorgin	2013	ACS medicinal chemistry letters, Apr-11, Volume: 4, Issue:4	Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.
AID1486982	Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1129603	Activation of ATPase activity of MDR1 (unknown origin) expressed in MDCK cells assessed as reduction of reduction of ATP level at 100 uM after 2 hrs by luminescence/ATPlite assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	SAR study on arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity.
AID1904128	Cytotoxicity against dog MDCK cells after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1192300	Inhibition of human MDR1 expressed in MDCK2 cells assessed as increase of rhodamine 123 uptake at 5 uM up to 240 mins	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Discovery of anthranilamides as a novel class of inhibitors of neurotropic alphavirus replication.
AID1385909	Inhibition of ABCG2 in human MCF7/Topo cells at 100 uM after 2 hrs by Hoechst 33342 staining based fluorescence assay relative to 10 uM FTC	2018	ACS medicinal chemistry letters, Aug-09, Volume: 9, Issue:8	Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators.
AID1785054	Reversal of resistance to paclitaxel-induced cytotoxicity in paclitaxel-resistant human SW-620/AD300 cells assessed as reduction in paclitaxel IC50 at 2 uM pre-incubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay
AID1328262	Inhibition of ABCB1 in human NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine resistance ratio at 1000 nM after 72 hrs by MTT assay relative to parental OVCAR8 cells (Rvb = 435 No_unit)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID295524	Growth inhibition of human CEM/VLB500 cells after 3 days by resazurin assay	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID1903299	Potentiation of vincristine-induced cytotoxicity against human KBV cells assessed as vincristine IC50 by measuring ratio IC50 as reversal fold at 5 uM for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles.
AID1328282	Inhibition of ABCB1 in human KBV1 cells assessed as potentiation of colchicine-induced apoptosis by measuring early apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 9.8%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1904174	Effect on BCRP expression in dog MDCK-II-BCRP cells at 5 uM measured by Western blot analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1668496	Reversal of human ABCB1-mediated multidrug resistance in HEK293/MDR19 cells assessed as fold change in colchicine IC50 at 1 uM after 72 hrs by CCK8 relative to colchicine IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID695835	Inhibition of P-gp in human KB-V1 cells assessed as increase in rhodamine 123 accumulation at 200 nM	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1832619	Chemo-sensitizing activity against ABCB1-oveexpressing human KB-V1 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1674912	Growth inhibition of human p53 +/+ H1299 cells upto 10 uM incubated for 48 hrs	2020	Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18	Mdm2 inhibitors as a platform for the design of P-glycoprotein inhibitors.
AID1129604	Efflux ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells at 100 uM after 30 mins by UV spectroscopy	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	SAR study on arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity.
AID1832655	Chemo-sensitizing activity against ABCB1-overexpressing human HEK293/MDR19 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1530712	Reversal of P-gp-mediated drug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring fold reduction in paclitaxel IC50 at 5 uM after 72 hrs by MTT assay relative to paclitaxel alone	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents.
AID1668504	Effect on Colchicine-induced cytotoxicity against HEK293 cells assessed as fold change in colchicine IC50 at 1 uM after 72 hrs by CCK8 assay relative to colchicine IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1277333	Inhibition of ABCG2 in human MCF7/Topo cells by Hoechst 33342 assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization.
AID1832643	Chemo-sensitizing activity against ABCB1-overexpressing human HEK293/MDR19 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID326370	Inhibition of mouse Pgp in EMT6/AR1.0 cells after 1 hr by daunorubicin accumulation assay	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors.
AID1328168	Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin resistance ratio at 1000 nM after 72 hrs by CCK8 assay relative to parental HEK293 cells (Rvb = 96 No_unit)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1244220	Cytotoxicity against human HepG2 cells at 200 nM after 72 hrs by SRB assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1761215	Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 10 uM measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
AID1832575	Chemo-sensitizing activity against human OVCAR-8 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1690372	Inhibition of ABCG2 in topotecan-cultured human MCF7 cells using Hoechst 33342 as substrate measured after 2 hrs by fluorescence assay	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1903289	Potentiation of mitoxantrone-induced cytotoxicity against human KBV cells assessed as mitoxantrone IC50 at 5 uM for 72 hrs by MTT assay (Rvb = 695.15 +/- 57.54 nM )	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles.
AID1832616	Chemo-sensitizing activity against human KB 3-1 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1328227	Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1832613	Chemo-sensitizing activity against ABCB1-overexpressing human KB-V1 cells assessed as colchicine IC50 at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay (Rvb = 758.22 +/-156.56 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1832625	Chemo-sensitizing activity against ABCB1-overexpressing human HEK293/MDR19 cells assessed as vincristine IC50 at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay (Rvb = 787.11 +/-227.51 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1738696	Inhibition of P-gp-mediated doxorubicin efflux in human K562/4 cells assessed as increase in intracellular doxorubicin accumulation at 1 to 10 uM pretreated with compound for 30 mins followed by incubation with doxorubicin for 2 hrs by flow cytometry	2020	European journal of medicinal chemistry, Jul-15, Volume: 198	Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin.
AID1244219	Cytotoxicity against human SW620/AD300 cells expressing p-glycoprotein at 200 nM after 72 hrs by SRB assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1674911	Growth inhibition of human p53 -/- NCI-HCT-116 cells upto 10 uM incubated for 48 hrs	2020	Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18	Mdm2 inhibitors as a platform for the design of P-glycoprotein inhibitors.
AID599026	Inhibition of ABCG2 expressed in human MCF7/Topo cells by Hoechst microplate assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).
AID1631729	Inhibition of P-gp mediated efflux in adriamycin-resistant human HepG2 cells assessed as intracellular rhodamine-123 accumulation at 2 uM incubated in dark condition for 90 mins by flow cytometry relative to control	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1328284	Inhibition of ABCB1 in human KBV1 cells assessed as potentiation of colchicine-induced apoptosis by measuring necrotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 1.9%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1328189	Inhibition of ABCB1 in human KBV1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin resistance ratio at 1000 nM after 72 hrs by MTT assay relative to parental KB-3-1 cells (Rvb = 34 No_unit)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID679894	TP_TRANSPORTER: inhibition of cyclosporin A transcellular transport by tariquidar at a concentration of 0.2uM in MDR1-expressing MDCKII cells	2007	Neuropharmacology, Feb, Volume: 52, Issue:2	Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
AID1391799	Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as reduction in cell viability after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors.
AID1673424	Reversal of P-gp mediated multidrug resistance in human K562/A02 cells overexpressing P-gp assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 5 uM preincubated for 24 hrs followed by compound washout and 24 hrs l	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID295531	Inhibition of human CYP2D6 expressed in insect microsome after 30 mins	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID1244222	Cytotoxicity against human MCF7 cells at 200 nM after 72 hrs by SRB assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID588993	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MDR1	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID1832584	Chemo-sensitizing activity against ABCB1-overexpressing human NCI/ADR-RES cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1668509	Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1750897	Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay
AID442338	Increase in P-gp-substrate 99mTc]sestaMIBI accumulation in tumor and heart of human with metastatic cancer at 150 mg, iv by imaging analysis	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials.
AID364884	Inhibition of P-gp in human adriamycin-resistant A2780 cells by Hoechst 33342 assay	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
AID451987	Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining	2010	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1	Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
AID1673427	Reversal of P-gp mediated multidrug resistance in human K562/A02 cells overexpressing P-gp assessed as fold reduction in doxorubicin IC50 at 5 uM preincubated for 24 hrs followed by compound washout and 6 hrs later incubated with doxorubicin and measured	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
AID1750943	Potentiation of adriamycin-induced apoptosis in human K562 cells assessed as viable cells at 5 uM incubated for 48 hrs in presence of 10 uM adriamycin by Annexin-V/FITC-based flow cytometry (Rvb = 52.8%)
AID1832563	Chemo-sensitizing activity against human OVCAR-8 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID599027	Inhibition of ABCB1 expressed in Kb-V1 cells after 10 mins by calcein-AM assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).
AID1486951	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 at 5 uM measured after 48 hrs by MTT assay (Rvb = 43.75 to 96.91 uM)	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1832495	Chemo-sensitizing activity against human OVCAR-8 cells assessed as colchicine IC50 at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay (Rvb = 28.73 +/-10.04 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID680922	TP_TRANSPORTER: Vinorelbine-induced cytotoxicity in P-gp positive tumor	2004	Anti-cancer drugs, Oct, Volume: 15, Issue:9	Ex vivo reversal of chemoresistance by tariquidar (XR9576).
AID1832652	Chemo-sensitizing activity against human HEK293 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of colchicine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1832637	Chemo-sensitizing activity against ABCB1-overexpressing human HEK293/MDR19 cells assessed as paclitaxel IC50 at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay (Rvb = 1.31 +/-0.2 microM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1761209	Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
AID1244209	Inhibition of MRP1 (unknown origin)-mediated calcein-AM efflux expressed in HEK293/MRP1 cells at 0.5 uM after 1 hr by flow cytometry	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1631744	Metabolic stability in Sprague-Dawley rat liver microsomes assessed as rate constant at 100 uM by HPLC-UV analysis	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1853008	Inhibition of recombinant human P-gp ATPase activity in presence of MgATP preincubated for 40 min measured after 20 min by Pgp-Glo assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1832569	Chemo-sensitizing activity against human OVCAR-8 cells assessed as paclitaxel IC50 at 1 uM measured after 72 hrs in presence of paclitaxel by CCK8 assay (Rvb = 2.62 +/-0.31 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1832587	Chemo-sensitizing activity against human KB 3-1 cells assessed as vincristine IC50 at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay (Rvb = 1.19 +/-0.39 nM)	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1750904	Reversal of BCRP-mediated multidrug resistance in MDCK-II cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM after 48 hrs by MTT assay relative to control
AID1690381	Inhibition of sulfasalazine-stimulated ABCB1 ATPase activity (unknown origin) expressed in baculovirus infected Sf9 insect cells using ATP as substrate measured after 1 hr by colorimetric assay	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1277331	Inhibition of human MRP1 transfected in MDCK2 cells assessed as inhibition of calcein-AM efflux	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization.
AID578761	Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID1328218	Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 277.68 +/- 56.61 nM)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1479723	Inhibition of ABCB1 in human A2780adr cells assessed as increase in accumulation of calcein AM at 10 uM preincubated for 30 mins followed by calcein AM addition measured every 60 secs for 60 mins by fluorescence assay relative to control	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.
AID1530709	Reversal of P-gp-mediated drug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 398.34 +/- 0.58 uM)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents.
AID1631742	Half life in Sprague-Dawley rat liver microsomes at 100 uM by HPLC-UV analysis	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1631736	Reversal of P-gp-mediated resistance in adriamycin-resistant human HepG2 cells assessed as reduction in ADR IC50 at 500 nM after 48 hrs by MTT assay relative to control	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
AID1903301	Potentiation of cisplatin-induced cytotoxicity against human KBV cells assessed as cisplatin IC50 by measuring ratio IC50 as reversal fold at 5 uM for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles.
AID1419459	Inhibition of P-gp in human K562/DOX cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring reduction in doxorubicin IC50 at 1 uM incubated for 72 hrs by MTT assay relative to control	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	N-alkanol-N-cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy.
AID1328233	Inhibition of ABCB1 in human NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin resistance ratio at 1000 nM after 72 hrs by MTT assay relative to parental OVCAR8 cells (Rvb = 46 No_unit)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID1486979	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured after 24 hrs by MTT assay (Rvb = 51.34 +/- 5.1 uM)	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1766766	Inhibition of paclitaxel stimulated- P-gp ATPase activity (unknown origin)	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
AID1530711	Reversal of P-gp-mediated drug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring fold reduction in paclitaxel IC50 at 10 uM after 72 hrs by MTT assay relative to paclitaxel alone	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents.
AID1244225	Cytotoxicity against human LCC6 cells expressing p-glycoprotein at 200 nM after 72 hrs by SRB assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1391810	Inhibition of P-gp in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring fold reduction in adriamycin IC50 at 5 uM preincubated for 24 hrs followed by compound wash out and subsequent addition of adriamycin after	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors.
AID1815938	Stimulation of P-gp in human multi-drug resistant NCI-H460/R cells assessed as decrease in Rho123 accumulation by measuring mean fluorescence intensity at 50 uM incubated for 30 mins in presence of rhodamine 123 by flow cytometry
AID1832589	Chemo-sensitizing activity against human KB 3-1 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of vincristine by CCK8 assay relative to control	2021	Journal of natural products, 09-24, Volume: 84, Issue:9	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1391798	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors.
AID1244223	Cytotoxicity against human MCF-7 FLV1000 cells expressing BCRP at 200 nM after 72 hrs by SRB assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
AID1785055	Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620/AD300 cells assessed as paclitaxel IC50 by measuring reversal fold at 2 uM pre-incubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay relative to
AID578759	Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID1486976	Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured after 6 hrs by MTT assay relative to ADR alone	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors.
AID1328273	Induction of apoptosis in human KBV1 cells assessed as viable cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based FACS analysis (Rvb = 86.1%)	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1.
AID295529	Inhibition of human CYP2C9 expressed in insect microsome after 45 mins	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (0.96)	18.2507
2000's	52 (25.00)	29.6817
2010's	122 (58.65)	24.3611
2020's	32 (15.38)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	16 (7.62%)	5.53%
Reviews	12 (5.71%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	182 (86.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.	3.15	1	0	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite
coumarin 2H-chromen-2-one: coumarin derivative	2.02	1	0	coumarins	fluorescent dye; human metabolite; plant metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.05	1	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
glycine [no description available]	2.06	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	7.31	1	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
hoe 33342 BXI-72: structure in first source	2.17	1	0	bibenzimidazole; N-methylpiperazine	fluorochrome
phenytoin [no description available]	3.13	5	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	3.15	1	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	3.15	1	0	N-acylglycine	Daphnia magna metabolite
bumetanide [no description available]	3.15	1	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	9.11	44	3	aromatic ether; nitrile; polyether; tertiary amino compound
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	2.03	1	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
celecoxib [no description available]	3.15	1	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cetirizine Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.	3.15	1	0	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.08	1	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	2.08	1	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	3.15	1	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	3.15	1	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
cystamine [no description available]	2.06	1	0	organic disulfide; primary amino compound	EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.76	3	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	3.15	1	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	3.15	1	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
thiorphan Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.	2.06	1	0	N-acyl-amino acid
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	2.01	1	0
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.17	1	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
fexofenadine fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.	3.61	2	0	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	2.07	1	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	3.43	1	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	3.15	1	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	3.15	1	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.43	2	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	2.03	1	0	carbohydrazide	antitubercular agent; drug allergen
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	2.48	2	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
loperamide Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	13.34	13	3	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	3.15	1	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	2.13	1	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	3.87	2	1	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	3.89	3	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
ethylmaleimide Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.	2.06	1	0	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	2.93	4	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	7.21	1	0	carbazoles
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	3.15	5	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
pilsicainide pilsicainide: structure given in first source. pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.	3.15	1	0	organic heterobicyclic compound; secondary carboxamide	anti-arrhythmia drug; sodium channel blocker
pindolol Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.	3.15	1	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
praziquantel azinox: Russian drug	2.1	1	0	isoquinolines
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	3.43	1	1	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	3.59	2	0	benzoic acids; sulfonamide	uricosuric drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	3.15	1	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	2.51	2	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
ranitidine [no description available]	3.15	1	0	aralkylamine
imatinib [no description available]	3.84	3	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.25	1	0
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.25	1	0	diarylmethane
tetraethylammonium Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)	3.15	1	0	quaternary ammonium ion
tiopronin Tiopronin: Sulfhydryl acylated derivative of GLYCINE.	2.06	1	0	N-acyl-amino acid
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	3.15	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2.04	1	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
penicillamine Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.	2.06	1	0	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	3.15	1	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	2.74	3	0	pilocarpine	antiglaucoma drug
vincristine [no description available]	2.31	1	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	2.03	1	0	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.05	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
phenylephrine Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.	2.15	1	0	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.	2.52	2	0	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	2.11	1	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
sulfobromophthalein sodium bromosulfophthalein sodium : An organic sodium salt that is the disodium salt of bromosulfophthalein.. bromosulfophthalein : An organosulfonic acid that consists of phthalide bearing four bromo substituents at positions 4, 5, 6 and 7 as well as two 4-hydroxy-3-sulfophenyl groups both located at position 1.	3.15	1	0	organic sodium salt	dye
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2.11	1	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
taurocholic acid Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.	3.15	1	0	amino sulfonic acid; bile acid taurine conjugate	human metabolite
anthranilamide [no description available]	2.44	2	0	substituted aniline
isatin tribulin: endogenous MONOAMINE OXIDASE inhibitory activity extractable into ethyl acetate found in brain and many mammalian tissues and fluids; ISATIN is a major component; produced in excess following alcohol withdrawal;	2.25	1	0	indoledione	EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2.03	1	0	xanthene
soman Soman: An organophosphorus compound that inhibits cholinesterase. It causes seizures and has been used as a chemical warfare agent.	2.8	3	0	phosphonic ester
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.08	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
acridines Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.	7.52	21	2	acridines; mancude organic heterotricyclic parent; polycyclic heteroarene	genotoxin
thiazoles [no description available]	2.08	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	2.03	1	0	diazine; pyrazines	Daphnia magna metabolite
limestone Calcium Carbonate: Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.. calcium carbonate : A calcium salt with formula CCaO3.	2.15	1	0	calcium salt; carbonate salt; inorganic calcium salt; one-carbon compound	antacid; fertilizer; food colouring; food firming agent
kainic acid Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.	2.48	2	0	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
flavone flavone: RN given refers to unlabeled cpd; structure given in first source. flavone : The simplest member of the class of flavones that consists of 4H-chromen-4-one bearing a phenyl substituent at position 2.	2.06	1	0	flavones	metabolite; nematicide
resazurin resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure	2.03	1	0	phenoxazine
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.06	1	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
Berberine chloride (TN) [no description available]	3.15	1	0	organic molecular entity
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	3.41	1	1	cyclic ketone; erythromycin
dehydroepiandrosterone sulfate Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone.	3.15	1	0	17-oxo steroid; steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite
vinblastine [no description available]	3.55	2	0
1-methylpyridinium 1-methylpyridinium: RN given refers to parent cpd	3.15	1	0	methylpyridines
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	2.03	1	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	3.15	1	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
acadesine [no description available]	2.41	1	0	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor
benorilate benorilate: was heading 1980-94 (see under SALICYLATES 1980-90); was BENORYLATE see under SALICYLATES 1975-79; BENORYLATE was see BENORILATE 1980-94; use SALICYLATES to search BENORILATE 1980-90 & BENORYLATE 1975-79; an ester of aspirin and paracetamol with analgesic, antipyretic, and anti-inflammatory activity used in the treatment of rheumatoid diseases; it has less severe side effects than aspirin	2.31	1	0	carbonyl compound
buthionine sulfoximine Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.	2.15	1	0	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	3.15	1	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.02	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
cephalexin Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.	3.15	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
1-deoxynojirimycin 1-deoxy-nojirimycin: structure in first source. duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.	2.02	1	0	2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid	anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	2.72	3	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
razoxane Razoxane: An antimitotic agent with immunosuppressive properties.	2	1	0	N-alkylpiperazine
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.04	1	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	3.81	2	1	pseudohalide anion	mitochondrial respiratory-chain inhibitor
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	3.15	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	7.36	19	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	3.84	3	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
ribavirin Rebetron: Rebetron is tradename	2.57	2	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	2.45	2	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	3.56	2	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefadroxil anhydrous Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.15	1	0	cephalosporin	antibacterial drug
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.15	1	0	cephalosporin	antibacterial drug; drug allergen
stepronin [no description available]	2.06	1	0	N-acyl-amino acid
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	3.15	1	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
fosphenytoin fosphenytoin: structure given in first & second source	2.04	1	0	imidazolidine-2,4-dione
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	3.15	1	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
niguldipine [no description available]	2.07	1	0	diarylmethane
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	3.15	1	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	3.86	3	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
lamivudine [no description available]	3.15	1	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
irinotecan [no description available]	3.54	2	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	3.15	1	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
emtricitabine Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.	3.15	1	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.47	2	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
vanadates Vanadates: Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects.. vanadate(3-) : A vanadium oxoanion that is a trianion with formula VO4 in which the vanadium is in the +5 oxidation state and is attached to four oxygen atoms.	2.48	2	0	trivalent inorganic anion; vanadium oxoanion	EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
thiolactic acid thiolactic acid: RN given refers to parent cpd	2.06	1	0	mercaptopropanoic acid
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	3.15	1	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.55	2	0	D-glucopyranose	epitope; mouse metabolite
fluorexon fluorexon: structure	2.01	1	0	xanthene dye	fluorochrome
repaglinide [no description available]	3.15	1	0	piperidines
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	3.15	1	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	7.25	1	0	1,2,3-triazole
cystine L-cystine : The L-enantiomer of the sulfur-containing amino acid cystine.	2.06	1	0	cystine zwitterion; cystine; L-cysteine derivative; non-proteinogenic L-alpha-amino acid	EC 1.2.1.11 (aspartate-semialdehyde dehydrogenase) inhibitor; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
tangeretin tangeretin: structure given in first source; from citrus plants; inhibits invasion of MO4 mouse cells into embryonic chick heart in vitro. tangeretin : A pentamethoxyflavone flavone with methoxy groups at positions 4', 5, 6 , 7 and 8.. pentamethoxyflavone : A methoxyflavone that is flavone substituted by a five methoxy groups.	2.06	1	0	pentamethoxyflavone	antineoplastic agent; plant metabolite
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.08	1	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
ubenimex ubenimex: growth inhibitor	3.15	1	0
7-hydroxystaurosporine [no description available]	2.02	1	0
hernandezine hernandezine: from Thalictrum glandulosissimum; structure given in first source; RN given refers to (1beta)-isomer; RN for cpd without isomeric designation not avail 3/91	2.13	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
nobiletin nobiletin : A methoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 8, 3' and 4' respectively.	2.06	1	0	methoxyflavone	antineoplastic agent; plant metabolite
vexibinol vexibinol: flavanol from Sophora; structure in first source; RN given refers to (S-(R,S))-isomer. sophoraflavanone G : A tetrahydroxyflavanone having a structure of naringenin bearing an additional hydroxyl substituent at position 2' as well as a (2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl (lavandulyl) substituent at position 8'.	2.31	1	0	(2S)-flavan-4-one; 4'-hydroxyflavanones; tetrahydroxyflavanone	antimalarial; antimicrobial agent; antioxidant; plant metabolite
pinostrobin [no description available]	2.06	1	0	monohydroxyflavanone; monomethoxyflavanone	antidote; plant metabolite
hederagenin [no description available]	2.98	3	0	dihydroxy monocarboxylic acid; pentacyclic triterpenoid; sapogenin	plant metabolite
5,7-dimethoxyflavone chrysin 5,7-dimethyl ether : A dimethoxyflavone that is the 5,7-dimethyl ether derivative of chrysin.	2.06	1	0	dimethoxyflavone	plant metabolite
zofenopril zofenopril: structure given in first source; SQ 26900 refers to K salt & SQ 26991 to Ca salt. zofenopril : A proline derivative that is 4-(phenylsulfanyl)-L-proline in which the amine proton is replaced by a (2S)-3-(benzoylsulfanyl)-2-methylpropanoyl group. A prodrug for zofenoprilat.	3.15	1	0	aryl sulfide; L-proline derivative; N-acyl-L-amino acid; thioester	anticonvulsant; apoptosis inhibitor; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug; vasodilator agent
lopinavir [no description available]	3.15	1	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
glycylsarcosine glycylsarcosine : A dipeptide obtained by formal condensation of the carboxy group of glycine with the amino group of sarcosine.	3.15	1	0	dipeptide zwitterion; dipeptide
6-methoxyflavanone 6-methoxyflavanone: structure in first source	2.06	1	0
racecadotril racecadotril: parenterally active enkephalinase inhibitor	2.06	1	0	N-acyl-amino acid
triptolide [no description available]	2.5	2	0	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite
tryptoquivaline tryptoquivaline: tremor-producing metabolite from Aspergillus clavatus; tetrapeptide derived from tryptophan, anthranilic acid, valine, & methylalanine; structure & N1 names previously assigned to tryptoquivaline C & tryptoquivaline D found to be incorrect & are revised in third source; see also record for tryptoquivalone; structure in third source	2.5	2	0
1-phenyl-2-decanoylamino-3-morpholino-1-propanol RV 538: noninactivating inhibitor of ceramide-UDPG glucosyltransferase; RN given for unspecified HCl; structure given in first source	2.02	1	0
dodecyl-beta-d-maltoside dodecyl beta-D-maltoside : A glycoside resulting from attachment of a dodecyl group to the reducing-end anomeric centre of a beta-maltose molecule.	2.55	2	0	disaccharide derivative; glycoside	detergent
aporphine aporphine: RN given refers to parent cpd without isomeric designation. aporphine : An isoquinoline alkaloid that is the N-methyl derivative of 5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline.	2.08	1	0	aporphine alkaloid; isoquinoline alkaloid fundamental parent; tertiary amino compound
cp 65,526 azidoprazosin: labeled with 125I	3.43	1	1
elacridar Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source	7.83	29	2
buthionine sulfoximine L-buthionine-(S,R)-sulfoximine : A 2-amino-4-(S-butylsulfonimidoyl)butanoic acid which has S-configuration. It is a inhibitor of gamma-glutamylcysteine synthetase and glutathione (GSH) biosynthesis and is capable of enhancing the apoptotic effects of several chemotherapeutic agents.	2.06	1	0	2-amino-4-(S-butylsulfonimidoyl)butanoic acid	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
pramipexole Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.	3.15	1	0	benzothiazoles; diamine	antidyskinesia agent; antiparkinson drug; dopamine agonist; radical scavenger
gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate: RN refers to Na salt	2.06	1	0
astragaloside a [no description available]	2.21	1	0
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.75	3	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	2.8	3	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
methotrexate [no description available]	3.15	1	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
salvinorin a salvinorin A: from the herb, Salvia divinorum	2.07	1	0	organic heterotricyclic compound; organooxygen compound	metabolite; oneirogen
sinensetin sinensetin: isolated from citrus fruit; exhibit antiadhesive action on platelets. sinensetin : A pentamethoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 3' and 4' respectively.	2.06	1	0	pentamethoxyflavone	plant metabolite
6-methoxyflavone 6-methoxyflavone: suppresses NFAT-mediated T cell activation; structure in first source	2.06	1	0	ether; flavonoids
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	5.82	2	2	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	3.15	1	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
3,3',4',5,6,7,8-heptamethoxyflavone 3,3',4',5,6,7,8-heptamethoxyflavone: has anti-inflammatory activity; isolated from citrus fruit; exhibit antiadhesive action on platelets	2.06	1	0	ether; flavonoids
zosuquidar trihydrochloride [no description available]	2.21	1	0
olmesartan olmesartan: an active metabolite of CS 866	3.15	1	0	biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent
varenicline Varenicline: A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.. varenicline : An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.	3.15	1	0
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	2.49	2	0	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.55	2	0
erlotinib [no description available]	2.41	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
lapatinib [no description available]	2.41	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
lacosamide Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.	2.08	1	0	N-acyl-amino acid
pheophorbide a pheophorbide a: split product of chlorophyll obtained by saponification of pheophytin	2.75	3	0
5-Hydroxy-7-methoxy-6-methylflavone [no description available]	2.06	1	0	ether; flavonoids
5,7-dimethoxy-2-phenyl-3,4-dihydro-2H-1-benzopyran-4-one [no description available]	2.06	1	0	ether; flavonoids
bortezomib [no description available]	2.54	2	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	3.57	2	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
tryptoquivaline fumitremorgin C : An organic heteropentacyclic compound that is a mycotoxic indole alkaloid produced by several fungi. A potent and specific inhibitor of the breast cancer resistance protein multidrug transporter.	4.71	8	0	aromatic ether; indole alkaloid; organic heteropentacyclic compound	breast cancer resistance protein inhibitor; mycotoxin
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	2	1	0
(2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol: reverses multidrug resistance; NSC 23925b is an isomer. structure in first source	3.27	1	0
dithiothreitol [no description available]	2.06	1	0	1,4-dithiothreitol
glucosamine D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.	2.02	1	0	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
cysteinylglycine cysteinylglycine: RN given refers to (L)-isomer; RN for cpd without isomeric designation not in Chemlne 7/13/83. L-cysteinylglycine : A dipeptide consisting of glycine having an L-cysteinyl attached to its alpha-amino group. It is an intermediate metabolite in glutathione metabolism.	2.06	1	0	dipeptide zwitterion; dipeptide	Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	3.15	1	0	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	4.27	5	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	3.15	1	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
naringin [no description available]	3.15	1	0	(2S)-flavan-4-one; 4'-hydroxyflavanones; dihydroxyflavanone; disaccharide derivative; neohesperidoside	anti-inflammatory agent; antineoplastic agent; metabolite
doxorubicin hydrochloride [no description available]	2.9	3	0	anthracycline
ergosterol [no description available]	3.51	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; ergostanoid; phytosterols	fungal metabolite; Saccharomyces cerevisiae metabolite
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	2.03	1	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	3.15	1	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	3.18	1	0	stilbene
azidopine azidopine: structure given in first source	2	1	0	benzamides
reversan reversan: inhibits multidrug resistance-associated protein 1	2.13	1	0
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	3.87	3	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
polysulfide rubber [no description available]	2.07	1	0
estrone sulfate estrone sulfate: sulfoconjugated estrone; RN given refers to parent cpd	3.15	1	0	17-oxo steroid; steroid sulfate	human metabolite; mouse metabolite
glycylproline Gly-Pro : A dipeptide consisting of L-proline having a glycyl residue attached to its alpha-amino group.	3.15	1	0	dipeptide zwitterion; dipeptide	metabolite
quinine [no description available]	3.15	1	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
ly335979 [no description available]	5.33	9	0	carbopolycyclic compound
biricodar biricodar: a non-macrocyclic ligand for FKBP12; structure in first source	3.51	2	0	alpha-amino acid ester
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.25	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
1-[[4-[(4-fluorophenyl)methyl]-5-thieno[3,2-b]pyrrolyl]-oxomethyl]-N-(2-furanylmethyl)-4-piperidinecarboxamide [no description available]	2.08	1	0	N-acylpiperidine
rhodamine 123 Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.	5.06	9	1	organic cation; xanthene dye	fluorochrome
quercetin [no description available]	2.79	3	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
bilirubin [no description available]	3.15	1	0	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.06	1	0	trihydroxyflavone	antineoplastic agent; metabolite
ayanin ayanin: has cytoprotective and anti-neuroinflammatory activities; isolated from Croton schiedeanus (Euphorbiaceae); structure in first source. 3',5-dihydroxy-3,4',7-trimethoxyflavone : A trimethoxyflavone that is quercetin in which the hydroxy groups at positions 3, 4' and 7 have been replaced by methoxy groups.	2.06	1	0	dihydroxyflavone; trimethoxyflavone	plant metabolite
apigetrin apigetrin: structure given in first source. apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.06	1	0	beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative	antibacterial agent; metabolite; non-steroidal anti-inflammatory drug
bilirubin diglucuronide [no description available]	3.15	1	0
kaempferol [no description available]	2.06	1	0	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
genistein [no description available]	2.06	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
chrysin chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.	2.06	1	0	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
hyperoside quercetin 3-O-beta-D-galactopyranoside : A quercetin O-glycoside that is quercetin with a beta-D-galactosyl residue attached at position 3. Isolated from Artemisia capillaris, it exhibits hepatoprotective activity.	2.06	1	0	beta-D-galactoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite
morin morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.	2.06	1	0	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
sdz psc 833 valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215	6.41	7	1	homodetic cyclic peptide
estradiol-17 beta-glucuronide 17beta-estradiol 17-glucosiduronic acid : A steroid glucosiduronic acid that consists of 17beta-estradiol having a beta-glucuronyl residue attached at position 17 via a glycosidic linkage.	3.15	1	0	3-hydroxy steroid; steroid glucosiduronic acid
l 660,711 [no description available]	3.04	4	0	quinolines
vitexin rhamnoside 2''-O-rhamnopyranosylvitexin: has both analgesic and anti-inflammatory activities; isolated from Alternanthera maritima; structure in first source. vitexin 2''-O-alpha-L-rhamnoside : A derivative of vitexin having an alpha-L-rhamnosyl residue attached at the 2''-position of the glucitol moiety.	2.06	1	0	C-glycosyl compound; disaccharide derivative; trihydroxyflavone	plant metabolite
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	4.76	9	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
levetiracetam Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.	2.03	1	0	pyrrolidin-2-ones	anticonvulsant; environmental contaminant; xenobiotic
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.15	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
licochalcone a licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer	2.25	1	0	chalcones
5,4'-dihydroxy-3,6,7-trimethoxyflavone 5,4'-dihydroxy-3,6,7-trimethoxyflavone: from Microliabum polymnioides; structure in first source	2.06	1	0
5-hydroxy-3,3',4',7-tetramethoxyflavone 5-hydroxy-3,7,3',4'-tetramethoxyflavone: from the rhizome of Kaempferia parviflora; inhibits monocyte adhesion and cellular reactive oxygen species production in human umbilical vein endothelial cells. 5-hydroxy-3,3',4',7-tetramethoxyflavone : A monohydroxyflavone that is 5-hydroxyflavone which is substituted by methoxy groups at positions 3,3',4' and 7.	2.06	1	0	3'-methoxyflavones; monohydroxyflavone; tetramethoxyflavone	plant metabolite
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine: structure given in first source. 1,1',3,3'-tetraethyl-5,5',6,6'-tetrachloroimidacarbocyanine : The cationic form of a C3 cyanine dye having 1,3-diethyl-5,6-dichloroindoleinine units at each end.	2.17	1	0	cyanine dye; indolium ion	fluorochrome
enalapril Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).	3.6	2	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.02	1	0	cysteinium	fundamental metabolite
vitexin rhamnoside vitexin rhamnoside: an apigenin	2.06	1	0	flavonoids; glycoside
carbocyanines Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.	2.17	1	0	cyanine dye; organic iodide salt	fluorochrome
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	2.04	1	0	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
ixabepilone [no description available]	3.27	1	0	1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle	antineoplastic agent; microtubule-destabilising agent
laniquidar laniquidar: structure in first source	3.54	2	0
oc 144-093 OC 144-093: inhibits P-glycoprotein-mediated drug resistance; structure in first source	3.55	2	0
ceftizoxime [no description available]	3.15	1	0	cephalosporin	antibacterial drug
beta-escin [no description available]	2.21	1	0
cyclo(prolyl-valyl) [no description available]	2.41	1	0	piperazinone	metabolite
staurosporine staurosporinium : Conjugate acid of staurosporine.	2.42	2	0	ammonium ion derivative
fosinopril [no description available]	3.15	1	0
n-demethylloperamide N-demethylloperamide: loperamide metabolite; structure in first source. desmethyl loperamide : A monocarboxylic acid amide that is the methylamide of 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-2,2-diphenylbutanoic acid.	6.04	5	2	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	drug metabolite
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	2	1	0	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	3.15	1	0	oligopeptide
cabazitaxel cabazitaxel: an antineoplastic agent; structure in first source. cabazitaxel : A tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly.	3.27	1	0	tetracyclic diterpenoid	antineoplastic agent; microtubule-stabilising agent
ko 143 [no description available]	3.82	10	0	beta-carbolines; tert-butyl ester
ningalin b ningalin B: structure in first source	2.25	1	0
n-isobutyrylglycine N-isobutyrylglycine: found in urine of patients with glyceric acidemia. N-isobutyrylglycine : An N-acylglycine in which the acyl group is specified as isobutryl.	2.06	1	0	N-acylglycine	human urinary metabolite
nutlin-3a nutlin 3: an MDM2 antagonist; structure in first source	2.69	2	0	stilbenoid
carfilzomib [no description available]	2.15	1	0	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
wk-x-34 WK-X-34: inhibitor of P-glycoprotein and BCRP (breast cancer resistance protein); structure in first source	2.74	3	0
scopolamine hydrobromide [no description available]	2.06	1	0
mefloquine Mefloquine: A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects.. mefloquine : A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.	2.08	1	0
quinoline-3-carboxamide quinoline-3-carboxamide: structure in first source	2.13	1	0
xr 9577 [no description available]	2.44	2	0
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	2.02	1	0	1,2-diacyl-sn-glycero-3-phosphocholine
chlorophyll a Chlorophyll: Porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms.. chlorophyll : A family of magnesium porphyrins, defined by the presence of a fifth ring beyond the four pyrrole-like rings. The rings can have various side chains which usually include a long phytol chain.	2.44	2	0	chlorophyll; methyl ester	cofactor
hoe 33342 bisbenzimide ethoxide trihydrochloride: benzimidazole fluorescent dye	2.44	2	0
mk 0571 [no description available]	2.13	1	0
technetium tc 99m sestamibi Technetium Tc 99m Sestamibi: A technetium imaging agent used to reveal blood-starved cardiac tissue during a heart attack.	6.67	3	2
taurocholic acid, monosodium salt [no description available]	3.15	1	0	bile salt
mefway mefway: a 5-HT(1A) receptor radioligand for PET imaging	2.13	1	0
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene [no description available]	2.53	2	0	BODIPY compound
glycolipids [no description available]	2.02	1	0
piperidines Piperidines: A family of hexahydropyridines.	4.57	4	0
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	4.06	4	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.02	1	0	benzenes; hydroxycoumarin; methyl ketone
amg 232 [no description available]	2.25	1	0
3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester: a breast cancer resistance protein (BCRP) inhibitor; structure in first source	2.78	3	0
ergost-7,22-diene-3-ol ergosta-7,22-dien-3-one: isolated from Ganoderma lucida	3.51	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	3.59	8	0
amyloid beta-peptides amyloid beta-protein (1-40): although acutely neurotoxic in both rat & monkey cerebral cortex, neuronal degeneration in primates resembles more closely to that found in Alzheimer's disease; amino acid sequence has been determined	2.31	1	0
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	3.15	1	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	3.15	1	0	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	2.57	2	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	3.83	3	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
valacyclovir Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.	3.15	1	0	L-valyl ester	antiviral drug
asoxime chloride [no description available]	2.8	3	0
phenanthrenes Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.	2.5	2	0

Condition	Indicated	Relationship Strength	Studies	Trials
Breast Cancer [description not available]	0	5.63	17	1
Breast Neoplasms Tumors or cancer of the human BREAST.	1	7.63	17	1
Cancer of Ovary [description not available]	0	5.06	3	1
Cancer of Skin [description not available]	0	2.02	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	1	7.06	3	1
Skin Neoplasms Tumors or cancer of the SKIN.	0	2.02	1	0
Degenerative Diseases, Central Nervous System [description not available]	0	2.97	1	0
Benign Neoplasms [description not available]	0	9.21	11	3
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	9.21	11	3
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	0	2.97	1	0
Experimental Hepatoma [description not available]	0	2.13	1	0
Experimental Neoplasms [description not available]	0	2.46	2	0
Granulocytic Leukemia [description not available]	0	2.25	1	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	0	2.25	1	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.57	8	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	2.31	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	1	4.31	1	0
Adenocarcinoma, Basal Cell [description not available]	0	3.44	2	0
Cancer of Colon [description not available]	0	3.33	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	3.44	2	0
Colonic Neoplasms Tumors or cancer of the COLON.	0	3.33	1	0
Disease Exacerbation [description not available]	0	2.31	1	0
Acute Confusional Senile Dementia [description not available]	0	2.31	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	0	2.31	1	0
Anoxemia [description not available]	0	2.15	1	0
Kahler Disease [description not available]	0	2.15	1	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	0	7.15	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	7.15	1	0
Angiostrongylus Infections [description not available]	0	2.15	1	0
Acute Hypercapnic Respiratory Failure [description not available]	0	2.17	1	0
Respiratory Insufficiency Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)	0	2.17	1	0
Absence Seizure [description not available]	0	3.45	7	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	0	3.45	7	0
Allergic Encephalomyelitis [description not available]	0	2.21	1	0
Brain Stem Neoplasms, Primary [description not available]	0	2.25	1	0
DIPG Brain Tumors [description not available]	0	2.25	1	0
Diffuse Intrinsic Pontine Glioma A rare, aggressive brain tumor that forms in the GLIAL CELLS in the PONS.	0	2.25	1	0
Brain Stem Neoplasms Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA.	0	2.25	1	0
Chronic Illness [description not available]	0	2.08	1	0
Recrudescence [description not available]	0	2.08	1	0
Aura [description not available]	0	4.22	6	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	2.08	1	0
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	0	4.22	6	0
Diathesis [description not available]	0	2.1	1	0
Bilharziasis [description not available]	0	2.1	1	0
Schistosomiasis Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States.	0	2.1	1	0
Acute Liver Injury, Drug-Induced [description not available]	0	2.11	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.11	1	0
Emesis [description not available]	0	4.41	1	1
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	0	4.41	1	1
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	5.34	2	2
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	0	4.41	1	1
Cancer of Stomach [description not available]	0	2.13	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	0	2.13	1	0
Absence Status [description not available]	0	2.74	3	0
Status Epilepticus A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)	0	2.74	3	0
Leukemia, Lymphocytic, T Cell [description not available]	0	2.05	1	0
Animal Mammary Carcinoma [description not available]	0	2.05	1	0
Leukemia, T-Cell A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.	0	2.05	1	0
Adverse Drug Event [description not available]	0	3.44	1	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	3.44	1	1
Benign Psychomotor Epilepsy, Childhood [description not available]	0	2.95	4	0
Epilepsy, Temporal Lobe A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the TEMPORAL LOBE, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic. (From Adams et al., Principles of Neurology, 6th ed, p321).	0	2.95	4	0
Cancer of Cervix [description not available]	0	4.37	1	1
Cancer of Lung [description not available]	0	4.37	1	1
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	0	4.37	1	1
Lung Neoplasms Tumors or cancer of the LUNG.	1	6.37	1	1
Ptosis, Eyelid [description not available]	0	2.07	1	0
Blepharoptosis Drooping of the upper lid due to deficient development or paralysis of the levator palpebrae muscle.	0	2.07	1	0
Cancer of Liver [description not available]	0	4.31	1	1
Metastase [description not available]	0	4.31	1	1
Liver Neoplasms Tumors or cancer of the LIVER.	0	4.31	1	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	4.31	1	1
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	0	2.01	1	0
Local Neoplasm Recurrence [description not available]	0	3.41	1	1
Ache [description not available]	0	2.03	1	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	0	2.03	1	0
Cerebral Ischemia [description not available]	0	2.03	1	0
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	0	2.03	1	0
Koch's Disease [description not available]	0	2.03	1	0
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	0	2.03	1	0
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	0	2.04	1	0
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	0	2	1	0

tariquidar

Cross-References

Synonyms (59)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (15)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (88)

Molecular Functions (67)

Ceullar Components (20)

Bioassays (326)

Research

Studies (208)

Market Indicators

Research Demand Index: 34.52

Study Types

tariquidar

Cross-References

Synonyms (59)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (15)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (88)

Molecular Functions (67)

Ceullar Components (20)

Bioassays (326)

Research

Studies (208)

Market Indicators

Research Demand Index: 34.52

Study Types

Related Drugs (277)

Related Conditions (85)